Helle Linnebjerg
-
- Diabetes Treatment and Management 39
- Diabetes Management and Research 36
- Surgery top 5%
- Pancreatic function and diabetes 27
- Lipoproteins and Cardiovascular Health 4
- Gastroenterology top 10%
- Pharmacology top 5%
- Pharmacology and Obesity Treatment 3
- Genetics top 10%
-
- Metabolism, Diabetes, and Cancer 5
-
- Antiplatelet Therapy and Cardiovascular Diseases 3
-
- Medication Adherence and Compliance 3
Helle Linnebjerg
57 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 87
- Endocrinology, Diabetes and Metabolism 1.3k
- Surgery 859
- Gastroenterology 64
- Pharmacology 196
- Genetics 186
Countries citing papers authored by Helle Linnebjerg
This map shows the geographic impact of Helle Linnebjerg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helle Linnebjerg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helle Linnebjerg more than expected).
Fields of papers citing papers by Helle Linnebjerg
This network shows the impact of papers produced by Helle Linnebjerg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helle Linnebjerg. The network helps show where Helle Linnebjerg may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Helle Linnebjerg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 3 | |
| 2 | Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formationbreakdown → | 2023 | 112 |
| 3 | 2021 | 19 | |
| 4 | 2020 | 15 | |
| 5 | 2020 | 47 | |
| 6 | 2020 | 45 | |
| 7 | 2020 | 4 | |
| 8 | 2020 | 26 | |
| 9 | 2018 | 5 | |
| 10 | 2017 | 7 | |
| 11 | 2015 | 42 | |
| 12 | 2012 | 52 | |
| 13 | 2009 | 12 | |
| 14 | 2008 | 207 | |
| 15 | 2008 | 7 | |
| 16 | 2007 | 142 | |
| 17 | 2006 | 48 | |
| 18 | 2005 | 53 | |
| 19 | 1995 | 1 | |
| 20 | 1989 | 3 |
About Helle Linnebjerg
Helle Linnebjerg is a scholar working on Endocrinology, Diabetes and Metabolism, Family Practice and Surgery, having authored 60 papers that have together received 1.7k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (39 papers), Diabetes Management and Research (36 papers), Pancreatic function and diabetes (27 papers), Metabolism, Diabetes, and Cancer (5 papers), Lipoproteins and Cardiovascular Health (4 papers), Pharmacology and Obesity Treatment (3 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Medication Adherence and Compliance (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.3k citations), Surgery (859 citations) and Gastroenterology (64 citations). Helle Linnebjerg has collaborated with scholars based in United States, Singapore and United Kingdom. Frequent co-authors include Kenneth Mace, Prajakti A. Kothare, Soomin Park, Michael Trautmann, Malcolm I. Mitchell, Mary Seger, Shobha Reddy, Mark Fineman, David E. Coutant and Danny Soon. Their work appears in journals such as JAMA, Journal of the American College of Cardiology and Diabetes Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.